We found that measuring the amount of α‐synuclein in L1CAM‐immunocaptured exosomes per milliliter of serum is the most consistent biomarker in differentiating PD from MSA or PSP + CBS across cohorts, as shown in Figure 1. Here, L1CAM is linked to supranuclear palsy, progressive, 1.